SGLT2 Inhibitors and Survival in Lung Cancer Patients With Diabetes

NCT07272057 | Not Yet Recruiting DMC

• 1 other identifier: SLC-DO
• Study Type: interventional
• Target: 200
• Locations: 0 countries
• Sites: N/A

Brief Summary

The goal of this clinical trial The goal of this clinical trial is to evaluate whether SGLT2 inhibitor drugs can extend overall survival or delay the progression of the tumor in patients with both advanced lung cancer and diabetes. It will also check if these drugs are safe for these patients. The main questions it aims to answer are:

• Does adding an SGLT2 inhibitor to standard cancer treatment improve survival?
• Does it cause more or fewer cardiovascular toxicity?
• What side effects do participants experience? Researchers will compare a group taking an SGLT2 inhibitor to a group not taking SGLT2 inhibitor to see if the drug works. Participants will:
• Be adults diagnosed with advanced lung cancer and type 2 diabetes.
• Take either the SGLT2 inhibitor pill or other hypoglycemic drugs once a day alongside their cancer treatment.
• Undergo regular clinical visits for monitoring, laboratory tests, and imaging studies

Conditions

Lung Cancer

Outcome Measures

Primary Outcomes (1)

• Number of Participants with death

  From enrollment to the end of treatment at 12 months

Secondary Outcomes (1)

• Number of Participants with new-onset atrial fibrillation/flutter, acute coronary syndrome, myocarditis, massive pericardial effusion, heart failure and third-degree atrioventricular block.

  From enrollment to the end of treatment at 12 months

Study Arms (2)

treatment group

EXPERIMENTAL

On the basis of standard cancer treatment, take dapagliflozin for at least three months, once a day, 10 mg each time.

Drug: SGLT-2 inhibitor

control group

SHAM COMPARATOR

Based on the standard treatment for tumors, for the treatment of diabetes, no dapagliflozin has been taken.

Other: Sham (No Treatment)

Interventions

Sham (No Treatment) OTHER

SGLT2 inhibitors are not used for patients with lung cancer and diabetes

control group

SGLT-2 inhibitor DRUG

SGLT2 inhibitors used for patients with lung cancer and diabetes

treatment group

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Lung cancer patients receiving standard anti-tumor treatment; type 2 diabetes; patients with a score of 0-2 assessed by Eastern Cooperative Oncology Group's performance status; the patients agreed to participate in this study.

You may not qualify if:

• Severe abnormalities in liver, kidney or heart functions; expected lifespan less than 3 months.

Sponsors & Collaborators

• Shanghai Chest Hospital: lead

MeSH Terms

Conditions

Lung Neoplasms

Interventions

Sodium-Glucose Transporter 2 Inhibitors; salicylhydroxamic acid

Condition Hierarchy (Ancestors)

Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Molecular Mechanisms of Pharmacological Action; Pharmacologic Actions; Chemical Actions and Uses; Hypoglycemic Agents; Physiological Effects of Drugs

Central Study Contacts

Jindong Chen

CONTACT

+862122200000; cjdxk2016@163.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Dr

Study Record Dates

• First Submitted: November 18, 2025
• First Posted: December 9, 2025
• Study Start: December 7, 2025
• Primary Completion (Estimated): October 7, 2026
• Study Completion (Estimated): November 7, 2026
• Last Updated: December 9, 2025

Record last verified: 2025-10

Data Sharing

• IPD Sharing: Will not share